


Corrigendum to: Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 Studies

Under the “Major Adverse Cardiovascular Events and Deep Vein Thrombosis/Pulmonary Embolism” heading, the first sentence should read: “Incidence of adjudicated serious MACE per 100 PYs was low through 1 year, with 2 patients each in the placebo- (0.34) and ustekinumab-treated (0.12) pooled IBD population (Table 3).” instead of “Incidence of adjudicated serious MACE per 100 PYs was low through 1 year, with 1 patient each in the placebo- (0.34) and ustekinumab-treated (0.12) pooled IBD population (Table 4).”

In Figure 1, the y-axis should be corrected by deleting “per 100 patient-years” to read: “Number of events.” Figure 1 has been updated as follows:



© 2021 Crohn's & Colitis Foundation. Published by Oxford University Press on behalf of Crohn's & Colitis Foundation. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<https://creativecommons.org/licenses/by-nc/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
 doi: 10.1093/ibd/izab014
 Published online 29 January 2021